Addressing the theoretical and clinical advantages of combination therapy with inhibitors of the renin-angiotensin-aldosterone system: Antihypertensive effects and benefits beyond BP control

Life Sciences

Volumn 86, Issue 9-10, 2010, Pages 289-299

  Ferrario, Carlos M ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Aliskiren; Angiotensin II; Angiotensin (1 7); Combination therapy; Hypertension; Prorenin renin receptor; Renin angiotensin aldosterone system (RAAS) inhibition

Indexed keywords

ALISKIREN; AMLODIPINE; ANGIOTENSIN; ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN I; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ANGIOTENSIN[1-12]; ANGIOTENSIN[1-7]; ANGIOTENSINOGEN; BENAZEPRIL; BRADYKININ; BRAIN NATRIURETIC PEPTIDE; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROCHLOROTHIAZIDE; IRBESARTAN; LISINOPRIL; LOSARTAN; PLACEBO; PRORENIN; RAMIPRIL; RENIN; RENIN INHIBITOR; TELMISARTAN; THIAZIDE DIURETIC AGENT; UNCLASSIFIED DRUG; VALSARTAN;

ALBUMINURIA; ALDOSTERONE BLOOD LEVEL; ALDOSTERONE RELEASE; ALDOSTERONE URINE LEVEL; ANGIONEUROTIC EDEMA; ANGIOTENSIN BLOOD LEVEL; ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; BINDING COMPETITION; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONGESTIVE HEART FAILURE; COUGHING; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DRUG CONTRAINDICATION; DRUG INDICATION; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG RESPONSE; DRUG TOLERABILITY; EDEMA; GENE EXPRESSION; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOTENSION; KIDNEY DISEASE; KIDNEY FUNCTION; MONOTHERAPY; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PHARMACODYNAMICS; PLASMA RENIN ACTIVITY; PROTEINURIA; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RENIN RELEASE; REVIEW; SIDE EFFECT; SYNCOPE; VASODILATATION;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DRUG THERAPY, COMBINATION; HUMANS; HYPERTENSION; RENIN-ANGIOTENSIN SYSTEM;

EID: 76849103296     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2009.11.020     Document Type: Review

References (108)

1. Alderman M.H., Ooi W.L., Cohen H., Madhavan S., Sealey J.E., Laragh J.H. Plasma renin activity: a risk factor for myocardial infarction in hypertensive patients. American Journal of Hypertension 1997, 10(1):1-8.
2. Andersen K., Weinberger M.H., Egan B., Constance C.M., Ali M.A., Jin J., Keefe D.L. Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial. Journal of Hypertension 2008, 26(3):589-599.
3. Andersen K., Weinberger M.H., Constance C.C., Ali M.A., Jin J.F., Prescott M.F., Keefe D.L. Comparative effects of aliskiren-based and ramipril-based therapy on the renin system during long-term (6months) treatment and withdrawal in patients with hypertension. Journal of the Renin Angiotensin Aldosterone System 2009, 10, 157-167.
4. Andraws R., Brown D.L. Effect of inhibition of the renin-angiotensin system on development of type 2 diabetes mellitus (meta-analysis of randomized trials). American Journal of Cardiology 2007, 99(7):1006-1012.
5. Arici M., Erdem Y. Dual blockade of the renin-angiotensin system for cardiorenal protection: an update. American Journal of Kidney Disease 2009, 53(2):332-345.
6. Athyros V.G., Mikhailidis D.P., Kakafika A.I., Tziomalos K., Karagiannis A. Angiotensin II reactivation and aldosterone escape phenomena in renin-angiotensin-aldosterone system blockade: is oral renin inhibition the solution?. Expert Opinion on Pharmacotherapy 2007, 8(5):529-535.
7. Atlas S.A. The renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition. Journal of Managed Care Pharmacy 2007, 13(8 Suppl S-b):S9-S20.
8. Azizi M., Ménard J., Bissery A., Guyenne T.T., Bura-Rivière A., Vaidyanathan S., Camisasca R.P. Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption. Journal of the American Society of Nephrology 2004, 15(12):3126-3133.
9. Azizi M., Webb R., Nussberger J., Hollenberg N.K. Renin inhibition with aliskiren: where are we now, and where are we going?. Journal of Hypertension 2006, 24(2):243-256.
10. Azizi M., Ménard J., Bissery A., Guyene T.T., Bura-Rivière A. Hormonal and hemodynamic effects of aliskiren and valsartan and their combination in sodium-replete normotensive individuals. Clinical Journal of the American Society of Nephrology 2007, 2(5):947-955.
11. Bair T.L., May H.T., Prescott M.F., Anderson J.L., Horne B.D., Penman J., Muhlestein J.B. Association between baseline levels of plasma renin activity and risk of cardiovascular events. Journal of the American College of Cardiology 2009, 53(10 Suppl A):A383. Abstract 1028-12.
12. Balamuthusamy S., Srinivasan L., Verma M., Adigopula S., Jalandara N., Hathiwala S., Smith E. Renin angiotensin system blockade and cardiovascular outcomes in patients with chronic kidney disease and proteinuria: a meta-analysis. American Heart Journal 2008, 155(5):791-805.
13. Berns J.S. Is angiotensin-converting enzyme inhibitor and angiotensin receptor blocker combination therapy better than monotherapy and safe in patients with CKD?. American Journal of Kidney Disease 2009, 53(2):192-196.
14. Brown N.J. Aldosterone and end-organ damage. Current Opinion in Nephrology and Hypertension 2005, 14(3):235-241.
15. Burnier M., Brunner H.R. Angiotensin II receptor antagonists. Lancet 2000, 355(9204):637-645.
16. Chobanian A.V., Bakris G.L., Black H.R., Cushman W.C., Green L.A., Izzo J.L., Jones D.W., Materson B.J., Oparil S., Wright J.T., Roccella E.J. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003, 42(6):1206-1252.
17. Chrysant S.G., Murray A.V., Hoppe U.C., Dattani D., Patel S., Hsu H., Zhang J. Long-term safety, tolerability and efficacy of aliskiren in combination with valsartan in patients with hypertension: a 6-month interim analysis. Current Medical Research and Opinion 2008, 24(4):1039-1047.
18. Cohn J.N., Goldman J.M. Establishing a new option for target-organ protection: rationale for ARB plus ACE inhibitor combination therapy. American Journal of Hypertension 2008, 21(3):248-256.
19. Crackower M.A., Sarao R., Oudit G.Y., Yagil C., Kozieradzki I., Scanga S.E., Oliveira-dos-Santos A.J., da Costa J., Zhang L., Pei Y., Scholey J., Ferrario C.M., Manoukian A.S., Chappell M.C., Backx P.H., Yagil Y., Penninger J.M. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature 2002, 417(6891):822-828.
20. Dechend R., Shagdarsuren E., Gratze P., Fiebeler A., Pilz B., Meiners S., Derer W., Feldman D.L., Webb R., Muller D.N. Low-dose renin inhibitor and low-dose AT1-receptor blocker therapy ameliorate target-organ damage in rats harbouring human renin and angiotensinogen genes. Journal of the Renin Angiotensin Aldosterone System 2007, 8(2):81-84.
21. Dicpinigaitis P.V. Angiotensin-converting enzyme inhibitor-induced cough: ACCP evidence-based clinical practice guidelines. Chest 2006, 129(1 Suppl):169S-173S.
22. Doulton T.W., He F.J., MacGregor G.A. Systematic review of combined angiotensin-converting enzyme inhibition and angiotensin receptor blockade in hypertension. Hypertension 2005, 45(5):880-886.
23. Drummond W., Munger M.A., Rafique E.M., Maboudian M., Khan M., Keefe D.L. Antihypertensive efficacy of the oral direct renin inhibitor aliskiren as add-on therapy in patients not responding to amlodipine monotherapy. Journal of Clinical Hypertension (Greenwich) 2007, 9(10):742-750.
24. Duprez D.A., Botha J., Charney A.N., Prescott M.F. Comparison of the effects of aliskiren- versus ramipril-based treatment regimens of plasma renin concentration and plasma renin activity in elderly patients with systolic hypertension. Presented at the 24th Annual Scientific Meeting and Exposition of the American Society of Hypertension, May 6-9, San Francisco, CA, USA 2009.
25. Faure S., Bureau A., Oudart N., Javellaud J., Fournier A., Achard J.M. Protective effect of candesartan in experimental ischemic stroke in the rat mediated by AT2 and AT4 receptors. Journal of Hypertension 2008, 26(10):2008-2015.
26. Ferrari P., Marti H.P., Pfister M., Frey F.J. Additive antiproteinuric effect of combined ACE inhibition and angiotensin II receptor blockade. Journal of Hypertension 2002, 20(1):125-130.
27. Ferrario C.M., Chappell M.C., Tallant E.A., Brosnihan K.B., Diz D.I. Counterregulatory actions of angiotensin-(1-7). Hypertension 1997, 30(3 Pt 2):535-541.
28. Ferrario C.M., Chappell M.C., Dean R.H., Iyer S.N. Novel angiotensin peptides regulate blood pressure, endothelial function, and natriuresis. Journal of the American Society of Nephrology 1998, 9(9):1716-1722.
29. Ferrario C.M., Jessup J., Chappell M.C., Averill D.B., Brosnihan K.B., Tallant E.A., Diz D.I., Gallagher P.E. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation 2005, 111(20):2605-2610.
30. Ferrario C.M., Trask A.J., Jessup J.A. Advances in biochemical and functional roles of angiotensin-converting enzyme 2 and angiotensin-(1-7) in regulation of cardiovascular function. American Journal of Physiology-Heart and Circulatory Physiology 2005, 289(6):H2281-H2290.
31. Ferrario C.M., Varagic J., Habibi J., Nagata S., Kato J., Chappell M.C., Trask A.J., Kitamura K., Whaley-Connell A., Sowers J.R. Differential regulation of angiotensin-(1-12) in plasma and cardiac tissue in response to bilateral nephrectomy. American Journal of Physiology-Heart and Circulatory Physiology 2009, 296(4):H1184-H1192.
32. Fisher N.D., Hollenberg N.K. Renin inhibition: what are the therapeutic opportunities?. Journal of the American Society of Nephrology 2005, 16(3):592-599.
33. Fisher N.D., Jan Danser A.H., Nussberger J., Dole W.P., Hollenberg N.K. Renal and hormonal responses to direct renin inhibition with aliskiren in healthy humans. Circulation 2008, 117(25):3199-3205.
34. Gallagher P.E., Ferrario C.M., Tallant E.A. MAP kinase/phosphatase pathway mediates the regulation of ACE2 by angiotensin peptides. American Journal of Physiology. Cell Physiology 2008, 295(5):C1169-C1174.
35. Geiger H., Barranco E., Gorostidi M., Taylor A., Zhang X., Xiang Z., Zhang J. Combination therapy with various combinations of aliskiren, valsartan, and hydrochlorothiazide in hypertensive patients not adequately responsive to hydrochlorothiazide alone. Journal of Clinical Hypertension (Greenwich) 2009, 11(6):324-332.
36. Hollenberg N.K., Fisher N.D., Price D.A. Pathways for angiotensin II generation in intact human tissue: evidence from comparative pharmacological interruption of the renin system. Hypertension 1998, 32(3):387-392.
37. Ibrahim M.M. RAS inhibition in hypertension. Journal of Human Hypertension 2006, 20(2):101-108.
38. Ichihara A., Hayashi M., Kaneshiro Y., Suzuki F., Nakagawa T., Tada Y., Koura Y., Nishiyama A., Okada H., Uddin M.N., Nabi A.H., Ishida Y., Inagami T., Saruta T. Inhibition of diabetic nephropathy by a decoy peptide corresponding to the "handle" region for nonproteolytic activation of prorenin. Journal of Clinical Investigation 2004, 114(8):1128-1135.
39. Ihara M., Urata H., Kinoshita A., Suzumiya J., Sasaguri M., Kikuchi M., Ideishi M., Arakawa K. Increased chymase-dependent angiotensin II formation in human atherosclerotic aorta. Hypertension 1999, 33(6):1399-1405.
40. Jensen C., Herold P., Brunner H.R. Aliskiren: the first renin inhibitor for clinical treatment. National Reviews Drug Discovery 2008, 7(5):399-410.
41. Jessup J.A., Trask A.J., Chappell M.C., Nagata S., Kato J., Kitamura K., Ferrario C.M. Localization of the novel angiotensin peptide, angiotensin-(1-12), in heart and kidney of hypertensive and normotensive rats. American Journal of Physiology-Heart and Circulatory Physiology 2008, 294(6):H2614-H2618.
42. Kamoi K. Aliskiren combined with losartan in diabetes and nephropathy. New England Journal of Medicine 2008, 359(10):1069-1070.
43. Krum H., Carson P., Farsang C., Maggioni A.P., Glazer R.D., Aknay N., Chiang Y.T., Cohn J.N. Effect of valsartan added to background ACE inhibitor therapy in patients with heart failure: results from Val-HeFT. European Journal of Heart Failure 2004, 6(7):937-945.
44. Kunz R., Friedrich C., Wolbers M., Mann J.F. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Annals of Internal Medicine 2008, 148(1):30-48.
45. Lakhdar R., Al-Mallah M.H., Lanfear D.E. Safety and tolerability of angiotensin-converting enzyme inhibitor versus the combination of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker in patients with left ventricular dysfunction: a systematic review and meta-analysis of randomized controlled trials. Journal of Cardiac Failure 2008, 14(3):181-188.
46. Lalouel J.-M., Rohrwasser A., Terreros D., Morgan T., Ward K. Angiotensinogen in essential hypertension: from genetics to nephrology. Journal American Society of Nephrology 2001, 12:606-615.
47. Latini R., Masson S., Anand I., Salio M., Hester A., Judd D., Barlera S., Maggioni A.P., Tognoni G., Cohn J.N. The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT. European Heart Journal 2004, 25(4):292-299.
48. Legrand D., Krzesinski J.M., Scheen A.J. What is the purpose of dual or triple inhibition of the renin-angiotensin-aldosterone system?. Revue Médicale Suisse 2008, 4(168):1792-1797.
49. Lifton R.P., Gharavi A.G., Geller D.S. Molecular mechanisms of human hypertension. Cell 2001, 104(4):545-556.
50. Lijnen P., Fagard R., Staessen J., Amery A. Effect of chronic diuretic treatment on the plasma renin-angiotensin-aldosterone system in essential hypertension. British Journal of Clinical Pharmacology 1981, 12(3):387-392.
51. Mancia G., De Backer G., Dominiczak A., Cifkova R., Fagard R., Germano G., Grassi G., Heagerty A.M., Kjeldsen S.E., Laurent S., Narkiewicz K., Ruilope L., Rynkiewicz A., Schmieder R.E., Boudier H.A., Zanchetti A. 2007 Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Journal of Hypertension 2007, 25(6):1105-1187.
52. Mann J.F., Schmieder R.E., McQueen M., Dyal L., Schumacher H., Pogue J., Wang X., Maggioni A., Budaj A., Chaithiraphan S., Dickstein K., Keltai M., Metsarinne K., Oto A., Parkhomenko A., Piegas L.S., Svendsen T.L., Teo K.K., Yusuf S. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008, 372(9638):547-553.
53. Masson S., Solomon S., Angelici L., Anand I.S., Prescott M., Maggioni A.P., Tognoni G., Cohn J.N. Plasma renin activity retains a strong prognostic value in patients with chronic HF, independent of ACE inhibitor or beta-blocker therapy. Data from the Valsartan Heart Failure (Val-HeFT) trial. Presented at the 31th Annual Congress of the European Society of Cardiology, August 29-September 2, Barcelona, Spain 2009.
54. McMurray J.J., Ostergren J., Swedberg K., Granger C.B., Held P., Michelson E.L., Olofsson B., Yusuf S., Pfeffer M.A. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003, 362(9386):767-771.
55. McMurray J.J., Pitt B., Latini R., Maggioni A.P., Solomon S.D., Keefe D.L., Ford J., Verma A., Lewsey J. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circulation Heart Failure 2008, 1:17-24.
56. Messerli F.H. The sudden demise of dual renin-angiotensin system blockade or the soft science of the surrogate end point. Journal of the American College of Cardiology 2009, 53(6):468-470.
57. Nagata S., Kato J., Sasaki K., Minamino N., Eto T., Kitamura K. Isolation and identification of proangiotensin-12, a possible component of the renin-angiotensin system. Biochemical and Biophysical Research Communications 2006, 350(4):1026-1031.
58. Nakao N., Yoshimura A., Morita H., Takada M., Kayano T., Ideura T. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003, 361(9352):117-124.
59. KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. American Journal of Kidney Disease 2007, 49(2 Suppl 2):S12-S154. National Kidney Foundation.
60. Nguyen G., Contrepas A. Physiology and pharmacology of the (pro)renin receptor. Current Opinion in Pharmacology 2008, 8(2):127-132.
61. Nguyen G., Delarue F., Burckle C., Bouzhir L., Giller T., Sraer J.D. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. Journal of Clinical Investigation 2002, 109(11):1417-1427.
62. Nussberger J., Wuerzner G., Jensen C., Brunner H.R. Angiotensin II suppression in humans by the orally active renin inhibitor aliskiren (SPP100): comparison with enalapril. Hypertension 2002, 39(1):E1-E8.
63. Nussberger J., Gradman A.H., Schmieder R.E., Lins R.L., Chiang Y., Prescott M.F. Plasma renin and the antihypertensive effect of the orally active renin inhibitor aliskiren in clinical hypertension. International Journal of Clinical Practice 2007, 61(9):1461-1468.
64. Oparil S., Yarows S.A., Patel S., Fang H., Zhang J., Satlin A. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet 2007, 370(9583):221-229.
65. Oparil S., Yarows S.A., Patel S., Zhang J., Satlin A. Dual inhibition of the renin system by aliskiren and valsartan. Lancet 2007, 370(9593):1126-1127.
66. Parving H.H., Persson F., Lewis J.B., Lewis E.J., Hollenberg N.K. Aliskiren combined with losartan in type 2 diabetes and nephropathy. New England Journal of Medicine 2008, 358(23):2433-2446.
67. Persson F., Rossing P., Schjoedt K.J., Juhl T., Tarnow L., Stehouwer C.D., Schalkwijk C., Boomsma F., Frandsen E., Parving H.H. Time course of the antiproteinuric and antihypertensive effects of direct renin inhibition in type 2 diabetes. Kidney International 2008, 73(12):1419-1425.
68. Persson F., Rossing P., Reinhard H., Juhl T., Stehouwer C.D., Schalkwijk C., Danser A.J., Boomsma F., Frandsen E., Parving H.H. Renal effects of aliskiren compared to and in combination with irbesartan in patients with type 2 diabetes, hypertension and albuminuria. Diabetes Care 2009, 32, 1873-1879.
69. Phillips C.O., Kashani A., Ko D.K., Francis G., Krumholz H.M. Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: a quantitative review of data from randomized clinical trials. Archives of Internal Medicine 2007, 167(18):1930-1936.
70. Pitt B., Zannad F., Remme W.J., Cody R., Castaigne A., Perez A., Palensky J., Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. New England Journal of Medicine 1999, 341(10):709-717.
71. Pitt B., Remme W., Zannad F., Neaton J., Martinez F., Roniker B., Bittman R., Hurley S., Kleiman J., Gatlin M. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. New England Journal of Medicine 2003, 348(14):1309-1321.
72. Pool J.L., Schmieder R.E., Azizi M., Aldigier J.C., Januszewicz A., Zidek W., Chiang Y., Satlin A. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. American Journal of Hypertension 2007, 20(1):11-20.
73. Prosser H.C., Forster M.E., Richards A.M., Pemberton C.J. Cardiac chymase converts rat proAngiotensin-12 (PA12) to angiotensin II: effects of PA12 upon cardiac haemodynamics. Cardiovascular Research 2009, 82(1):40-50.
74. Remuzzi G., Cattaneo D., Perico N. The aggravating mechanisms of aldosterone on kidney fibrosis. Journal of the American Society of Nephrology 2008, 19(8):1459-1462.
75. Roig E., Perez-Villa F., Morales M., Jimenez W., Orus J., Heras M., Sanz G. Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure. European Heart Journal 2000, 21(1):53-57.
76. Santos R.A., Brosnihan K.B., Jacobsen D.W., DiCorleto P.E., Ferrario C.M. Production of angiotensin-(1-7) by human vascular endothelium. Hypertension 1992, 19(2 Suppl):II56-II61.
77. Santos R.A., Simoes e Silva A.C., Maric C., Silva D.M., Machado R.P., de B I., Heringer-Walther S., Pinheiro S.V., Lopes M.T., Bader M., Mendes E.P., Lemos V.S., Campagnole-Santos M.J., Schultheiss H.P., Speth R., Walther T. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proceedings of the National Academy of Sciences of the United States of America 2003, 100(14):8258-8263.
78. Sarafidis P.A., Bakris G.L. Renin-angiotensin blockade and kidney disease. Lancet 2008, 372(9638):511-512.
79. Schiavone M.T., Santos R.A., Brosnihan K.B., Khosla M.C., Ferrario C.M. Release of vasopressin from the rat hypothalamo-neurohypophysial system by angiotensin-(1-7) heptapeptide. Proceedings of the National Academy of Sciences of the United States of America 1988, 85(11):4095-4098.
80. Schiffrin E.L., Lipman M.L., Mann J.F. Chronic kidney disease: effects on the cardiovascular system. Circulation 2007, 116(1):85-97.
81. Schindler C., Bramlage P., Kirch W., Ferrario C.M. Role of the vasodilator peptide angiotensin-(1-7) in cardiovascular drug therapy. Vascular Health and Risk Management 2007, 3(1):125-137.
82. Sever P.S., Gradman A.H., Azizi M. Managing cardiovascular and renal risk: the potential of direct renin inhibition. Journal of the Renin Angiotensin Aldosterone System 2009, 10(2):65-76.
83. Solomon S.D., Appelbaum E., Manning W.J., Verma A., Berglund T., Lukashevich V., Cherif P.C., Smith B.A., Dahlöf B. Effect of the direct renin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation 2009, 119(4):530-537.
84. Stergiou G.S., Makris T., Papavasiliou M., Efstathiou S., Manolis A. Comparison of antihypertensive effects of an angiotensin-converting enzyme inhibitor, a calcium antagonist and a diuretic in patients with hypertension not controlled by angiotensin receptor blocker monotherapy. Journal of Hypertension 2005, 23(4):883-889.
85. Strauss M.H., Hall A.S. Angiotensin receptor blockers may increase risk of myocardial infarction: unraveling the ARB-MI paradox. Circulation 2006, 114(8):838-854.
86. Tallant E.A., Ferrario C.M., Gallagher P.E. Angiotensin-(1-7) inhibits growth of cardiac myocytes through activation of the mas receptor. American Journal of Physiology-Heart and Circulatory Physiology 2005, 289(4):H1560-H1566.
87. Trask A.J., Ferrario C.M. Angiotensin-(1-7): pharmacology and new perspectives in cardiovascular treatments. Cardiovascular Drug Reviews 2007, 25(2):162-174.
88. Trask A.J., Jessup J.A., Chappell M.C., Ferrario C.M. Angiotensin-(1-12) is an alternate substrate for angiotensin peptide production in the heart. American Journal of Physiology-Heart and Circulatory Physiology 2008, 294(5):H2242-H2247.
89. Turner A.J., Tipnis S.R., Guy J.L., Rice G., Hooper N.M. ACEH/ACE2 is a novel mammalian metallocarboxypeptidase and a homologue of angiotensin-converting enzyme insensitive to ACE inhibitors. Canadian Journal of Physiology and Pharmacology 2002, 80(4):346-353.
90. Unger T., Stoppelhaar M. Rationale for double renin-angiotensin-aldosterone system blockade. American Journal of Cardiology 2007, 100(3A):25J-31J.
91. Uresin Y., Taylor A.A., Kilo C., Tschöpe D., Santonastaso M., Ibram G., Fang H., Satlin A. Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension. Journal of the Renin Angiotensin Aldosterone System 2007, 8(4):190-198.
92. van de Wal R.M., Van Veldhuisen D.J., Van Gilst W.H., Voors A.A. Addition of an angiotensin receptor blocker to full-dose ACE-inhibition: controversial or common sense?. European Heart Journal 2005, 26(22):2361-2367.
93. Vergaro G., Fontana M., Poletti R., Giannoni A., Iervasi A.L., Masi L., Mammini C., Gabutti A., Passino C., Emdin M. Plasma renin activity is an independent prognostic factor in chronic heart failure. European Heart Journal 2008, 29(Suppl 1):393. Abstract 2493.
94. Vickers C., Hales P., Kaushik V., Dick L., Gavin J., Tang J., Godbout K., Parsons T., Baronas E., Hsieh F., Acton S., Patane M., Nichols A., Tummino P. Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. Journal of Biological Chemistry 2002, 277(17):14838-14843.
95. Villamil A., Chrysant S.G., Calhoun D., Schober B., Hsu H., Matrisciano-Dimichino L., Zhang J. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. Journal of Hypertension 2007, 25(1):217-226.
96. Vinh A., Widdop R.E., Drummond G.R., Gaspari T.A. Chronic angiotensin IV treatment reverses endothelial dysfunction in ApoE-deficient mice. Cardiovascular Research 2008, 77(1):178-187.
97. Waeber B., Aschwanden R., Sadecky L., Ferber P. Combination of hydrochlorothiazide or benazepril with valsartan in hypertensive patients unresponsive to valsartan alone. Journal of Hypertension 2001, 19(11):2097-2104.
98. Weber M.A., Giles T.D. Inhibiting the renin-angiotensin system to prevent cardiovascular diseases: do we need a more comprehensive strategy?. Reviews in Cardiovascular Medicine 2006, 7(2):45-54.
99. Weir M.R., Dzau V.J. The renin-angiotensin-aldosterone system: a specific target for hypertension management. American Journal of Hypertension 1999, 12(12 Pt 3):205S-213S.
100. Weir M.R., Smith D.H., Neutel J.M., Bedigian M.P. Valsartan alone or with a diuretic or ACE inhibitor as treatment for African American hypertensives: relation to salt intake. American Journal of Hypertension 2001, 14(7 Pt 1):665-671.
101. Weir M.R., Bush C., Anderson D.R., Zhang J., Keefe D., Satlin A. Antihypertensive efficacy, safety, and tolerability of the oral direct renin inhibitor aliskiren in patients with hypertension: a pooled analysis. Journal of the American Society of Hypertension 2007, 1(4):264-277.
102. Welches W.R., Brosnihan K.B., Ferrario C.M. A comparison of the properties and enzymatic activities of three angiotensin processing enzymes: angiotensin converting enzyme, prolyl endopeptidase and neutral endopeptidase 24.11. Life Sciences 1993, 52(18):1461-1480.
103. White H.D., Aylward P.E., Huang Z., Dalby A.J., Weaver W.D., Barvik S., Marin-Neto J.A., Murin J., Nordlander R.O., Van Gilst W.H., Zannad F., McMurray J.J., Califf R.M., Pfeffer M.A. Mortality and morbidity remain high despite captopril and/or valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction: results from the Valsartan in Acute Myocardial Infarction Trial (VALIANT). Circulation 2005, 112(22):3391-3399.
104. Wolf G., Ritz E. Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications. Kidney International 2005, 67(3):799-812.
105. Wong J., Patel R.A., Kowey P.R. The clinical use of angiotensin-converting enzyme inhibitors. Progress in Cardiovascular Diseases 2004, 47(2):116-130.
106. Yamamoto K., Chappell M.C., Brosnihan K.B., Ferrario C.M. In vivo metabolism of angiotensin I by neutral endopeptidase (EC 3.4.24.11) in spontaneously hypertensive rats. Hypertension 1992, 19(6 Pt 2):692-696.
107. Yarows S.A., Oparil S., Patel S., Fang H., Zhang J. Aliskiren and valsartan in stage 2 hypertension: subgroup analysis of a randomized, double-blind study. Advances in Therapy 2008, 25(12):1288-1302.
108. Yusuf S., Teo K.K., Pogue J., Dyal L., Copland I., Schumacher H., Dagenais G., Sleight P., Anderson C. Telmisartan, ramipril, or both in patients at high risk for vascular events. New England Journal of Medicine 2008, 358(15):1547-1559.